Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
AI Memory Chip Shortage Likely to Persist Despite Korea Investment Boom, Nomura Says 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
The US Justice Department charged Israeli generic drug firm Teva for conspiring to price-fixing, rigging bids, and allocating customers for generic drugs between 2013 and 2015.
The alleged transgressions caused patients to overpay by over $350 million.
Among the generic drugs was the cholesterol-regulating Pravastatin.
Teva, which sold $17 billion worth of drugs last year, rejected the charges saying it was “deeply disappointed" that the government proceeded with the prosecution.
It added that the US was unwilling to consider alternatives that would not be as impactful.
Five companies investigated in the case, including Sandoz, Taro, and Apotex have already paid fines to avoid prosecution.
Sandoz paid $195 million in March, while Apotex agreed to a $24.1 million fine in May.
In July, the American subsidiary of Israel's Taro Pharmaceuticals paid $205.7 million.
Earlier this month, Teva was also accused of inflating the reimbursement price for its multiple sclerosis drug, Copaxone, for patients in the Medicare program.
